News

Despite the lack of headlines today as compared to late last year, the drug-shortage situation has not improved. FDA, congressional and industry actions are beginning the change the dynamic

Sampling and doctors’ meetings compete for the largest secondary promotional spending component, behind detailing, in the BRIC countries

Biggest impact is expansion of user fees paid to FDA by generic and medical device manufacturers; drug approvals could be accelerated by changed review process; federal drug pedigree rules are 'on life support' but could still pass

Congress looks to a July passage of the Prescription Drug User Fee Act—with or without drug-tracking and wholesaler regulation

Press reports of the acquisition of Dik Drug Co. remain uncorroborated by Cardinal

Press reports of the acquisition of Dik Drug Co. remain uncorroborated by Cardinal

Physician's Sunshine Act rules will not go into effect until 2013, with public reporting possible in 2014

Physician's Sunshine Act rules will not go into effect until 2013, with public reporting possible in 2014

Starting with the NovaPure brand, company will build out QbD design principles for its product lines

Latest forecast from Pharmaceutical Commerce sees 37% growth between 2010-2013; delays in biosimilars commercialization will hamper future growth

Genpact survey of finance offices at major life sciences companies finds that half believe their strategic financial performance is poor

RFID-based system is said to provide lower-cost option that is better integrated into supply chain processes

Case involves the $75-million Eli Lilly heist in 2010, as well as multiple cargo truck thefts in 2009 and 2010

Compiling and maintaining lists of healthcare provider contacts is a bigger and more important task than ever

Case revolved around AWP pricing data between McKesson and First DataBank from 2005

Analysis of 'pharmacy related waste' finds $408 billion in potential annual savings

New services complement existing cloud services for life sciences; Berg Pharma is an early client

H. D. Smith specialty subsidiary targets emerging biotechs; Cardium goes with Web-only sales outreach initially

Meanwhile, a $274-million scandal is brewing over diverted HIV drugs in New York

Dohmen, DDN parent, also adds to its regulatory services with acquisition of BioSoteria

Quintiles will apply the predictive simulation capabilities of the Archimedes Model to drug development and commercialization

Decision could have broad implications for reps’ job status, and could undercut efforts to upgrade rep responsibilities

Major expansions in Argentina and Singapore point to heightened biopharma focus on emerging markets

Patient office visits, prescription usage continued to decline

Good design of vaults and cages for DEA-regulated materials calls for meeting regulatory requirements while accommodating operational practices

Latest annual Progressions report highlights the shift to healthy behaviors

Company continues to expand network of international supply depots